NeoGenomics (NEO) Releases Q1 2026 Earnings: Revenue Up 11.1% but EPS Misses

NeoGenomics Inc. (NEO) reported first-quarter 2026 results for the quarter ended March 31, 2026.

Revenue: $186.7 million, up 11.1% year-over-year.

Gross profit: $80.9 million, up 10.4% year-over-year.

Operating profit: -$18.2 million, down 34.4% year-over-year.

Net income attributable to common shareholders: -$17.1 million, down 34.0% year-over-year.

Diluted earnings per share: -$0.13, down 35.0% year-over-year.

Results versus expectations:

Revenue came in slightly above the consensus estimate of $186.4 million, beating by about $0.3 million.

Diluted EPS of -$0.13 missed the estimate of $0.0072 per share.

Cash flow and balance sheet highlights:

Cash from operating activities: -$8.1 million, down 67.9% year-over-year.

Purchases of property, plant and equipment: -$5.0 million, up 11.1% year-over-year.

Cash and cash equivalents: $164.1 million, down 52.6% year-over-year.

Cost of sales: $105.8 million, up 11.6% year-over-year.

Total liabilities: $517.8 million, down 27.4% year-over-year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

NeoGenomics Inc. Insider Trading Activity

NeoGenomics Inc. insiders have traded $NEO stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $NEO stock by insiders over the last 6 months:

WARREN STONE (Pres & Chief Operating Officer) sold 22,128 shares for an estimated $276,681
ALICIA C OLIVO (EVP, GC & Business Development) sold 20,916 shares for an estimated $250,992

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

NeoGenomics Inc. Hedge Fund Activity

We have seen 113 institutional investors add shares of NeoGenomics Inc. stock to their portfolio, and 127 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. removed 4,447,331 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $52,300,612
BRAIDWELL LP added 2,861,655 shares (+161.6%) to their portfolio in Q4 2025, for an estimated $33,653,062
MACQUARIE GROUP LTD removed 2,542,339 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,897,906
DRIEHAUS CAPITAL MANAGEMENT LLC added 2,471,738 shares (+inf%) to their portfolio in Q4 2025, for an estimated $29,067,638
D. E. SHAW & CO., INC. added 2,000,123 shares (+60.7%) to their portfolio in Q4 2025, for an estimated $23,521,446
LOOMIS SAYLES & CO L P added 1,631,135 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,182,147
CITADEL ADVISORS LLC removed 1,403,320 shares (-51.8%) from their portfolio in Q4 2025, for an estimated $16,503,043

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

NeoGenomics Inc. Government Contracts

We have seen $4,613,770 of award payments to $NEO over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

STX SPECIALIZED REFERENCE LABORATORY TESTING: $2,787,350
TASK ORDER FOR SERVICES ORDERING PERIOD 5 OFF-SITE ANATOMIC PATHOLOGY LAB SERVICES VACCHCS: $325,000
IMMUNOHISTOCHEMISTRY (IHC) TESTING: $211,500
IMMUNOHISTOLOGICAL STAINS REFERENCE TESTING: $108,000
[25-010222] HEMATOLOGY BRANCH/WIESTNER LABORATORY REQUIRES HUMAN GENOMICS TESTING SERVICES IN ORDER TO DIAG...: $24,614

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

NeoGenomics Inc. Analyst Ratings

Wall Street analysts have issued reports on $NEO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/17/2026

To track analyst ratings and price targets for NeoGenomics Inc., check out Quiver Quantitative's $NEO forecast page.

NeoGenomics Inc. Price Targets

Multiple analysts have issued price targets for $NEO recently. We have seen 2 analysts offer price targets for $NEO in the last 6 months, with a median target of $14.0.

Here are some recent targets:

David Westenberg from Piper Sandler set a target price of $13.0 on 02/24/2026
Mike Matson from Needham set a target price of $15.0 on 02/17/2026